EZOFITIMOD NEW DRUG IN SARCOIDOSIS PPT.pdf

A novel IV biological immunomodulator
Efzofitimod works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses
Composed of a splice variant of histidyl-tRNA synthetase

1. EFZOFITIMOD
PULMO @ RKG

2. EFZOFITIMOD
A novel IV biological immunomodulator
Efzofitimod works by selectively modulating Neuropilin-2 (NRP2) to
downregulate the innate and adaptive immune responses
Composed of a splice variant of histidyl-tRNA synthetase

3. Neuropilin upregulated in inflammatory cells in granuloma
In preclinical studies Efzofitimode regulate inflammation and decrease inflammation and lung
fibrosis.

4. RCT BY DANIEL A. CULVER ET AL
▪Drug well tolerated and no significant adverse effect
▪No immunogenicity reported lack of antidrug antibody at 24 weeks
▪Lower corticosteroids use in Efzofitmode arm in dose (depended)
▪Improvement in FVC and DLCO in treatment arm dose depended manner
(statistically non significant)

5. REFERENCES
Efzofitimod for the Treatment of Pulmonary Sarcoidosis Daniel A. Culver, DO;
Shambhu Aryal, MD; Joseph Barney, MD; Connie C. W. Hsia, MD; W. Ennis James,
MD; Lisa A. Maier, MD; Lucian T. Marts, MD; Ogugua Ndili Obi, MD, MPH; Peter H. S.
Sporn, MD; Nadera J. Sweiss, MD; Sanjay Shukla, MD; Nelson Kinnersley, PhD;
Gennyne Walker, PhD; and Robert Baughman, MD